scholarly journals Did the weight loss in the Prevention of Diabetes and Obesity in South Asians (PODOSA) trial differ by sex? An exploratory analysis

Public Health ◽  
2017 ◽  
Vol 145 ◽  
pp. 67-69 ◽  
Author(s):  
G. Cezard ◽  
A. Douglas ◽  
J.M.R. Gill ◽  
J. McKnight ◽  
A. Sheikh ◽  
...  
2013 ◽  
Vol 29 (4) ◽  
pp. 768-779 ◽  
Author(s):  
S. Wallia ◽  
R. S. Bhopal ◽  
A. Douglas ◽  
R. Bhopal ◽  
A. Sharma ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
pp. 61-69
Author(s):  
James EL Mackintosh ◽  
Jeminie Patel Mistry ◽  
Sarah N Ali ◽  
Vinod Patel

Protein is the most satiating macronutrient. Animal studies have indicated that there may be a discrete amount of protein that an individual seeks to consume each day. Given this to be true, a person will continue to eat until this amount of protein has been consumed. Once the target is met, hunger signals are switched off. By altering the proportion of protein in a diet, you can affect how many calories are required to meet this target. A diet with a protein content >15% drives weight loss through the reduction of calories consumed to meet protein needs. We hypothesise that changing the proportion of calories from protein in a person’s diet from 12% to 20% could alter their total intake by 1000 kcal each day. This equates to a weight change of 0.9 kg each week. Maintaining a healthy weight is not as simple as changing a single variable. Eating habits in the UK are governed by a range of complex interdependent factors including hunger, emotions, cost, accessibility, education and culture. However, we suggest that by addressing satiety, and thereby hunger, we may remove a significant barrier for those trying to alter their diet for weight loss.


2003 ◽  
Vol 3 (1_suppl) ◽  
pp. S12-S17
Author(s):  
Mike Lean

It is well established that the incidences of type 2 diabetes and impaired glucose tolerance are very low at ideal body weight (body mass index [BMI] 21—22 kg/m2) but increases with increasing body fat and BMI. Adipose tissue is an active endocrine organ which secretes many hormones involved in the regulation of body weight and appetite, including leptin and tumour necrosis factor-alpha, which are related to diabetes development. Weight loss is an important goal within the overall management of diabetes, and recent intervention trials have established that the benefits of weight loss may extend to the prevention of diabetes itself. Weight loss associated with diet and exercise in the DPP and the FDPS, by the anti-obesity drug orlistat in the XENDOS trial, and by gastric surgery in the SOS study all significantly reduced the incidence of diabetes compared with controls. The prevention or reversal of obesity is therefore an increasingly important therapeutic target in the prevention of type 2 diabetes.


BMJ Open ◽  
2014 ◽  
Vol 4 (6) ◽  
pp. e004736-e004736 ◽  
Author(s):  
Z. Morrison ◽  
A. Douglas ◽  
R. Bhopal ◽  
A. Sheikh ◽  
J. F. Forbes ◽  
...  

2012 ◽  
Vol 215 (3) ◽  
pp. 335-346 ◽  
Author(s):  
Alessandro Pocai

Oxyntomodulin (OXM) is a peptide secreted from the L cells of the gut following nutrient ingestion. OXM is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) combining the effects of GLP1 and glucagon to act as a potentially more effective treatment for obesity than GLP1R agonists. Injections of OXM in humans cause a significant reduction in weight and appetite, as well as an increase in energy expenditure. Activation of GCGR is classically associated with an elevation in glucose levels, which would be deleterious in patients with T2DM, but the antidiabetic properties of GLP1R agonism would be expected to counteract this effect. Indeed, OXM administration improved glucose tolerance in diet-induced obese mice. Thus, dual agonists of the GCGR and GLP1R represent a new therapeutic approach for diabetes and obesity with the potential for enhanced weight loss and improvement in glycemic control beyond those of GLP1R agonists.


Sign in / Sign up

Export Citation Format

Share Document